International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- PMID: 25439696
- DOI: 10.1016/S1470-2045(14)70442-5
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Abstract
This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and radiographic variables that fulfil the criteria for the presence of myeloma-defining CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specific metrics that new biomarkers should meet for inclusion in the disease definition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any differences in outcome that might occur as a result of the new disease definition.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Updated Diagnostic Criteria and Staging System for Multiple Myeloma.Am Soc Clin Oncol Educ Book. 2016;35:e418-23. doi: 10.1200/EDBK_159009. Am Soc Clin Oncol Educ Book. 2016. PMID: 27249749 Review.
-
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.Br J Haematol. 2003 Jun;121(5):749-57. Br J Haematol. 2003. PMID: 12780789
-
Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.Best Pract Res Clin Haematol. 2007 Dec;20(4):665-80. doi: 10.1016/j.beha.2007.10.002. Best Pract Res Clin Haematol. 2007. PMID: 18070712 Review.
-
Evolving diagnostic criteria for multiple myeloma.Hematology Am Soc Hematol Educ Program. 2015;2015:272-8. doi: 10.1182/asheducation-2015.1.272. Hematology Am Soc Hematol Educ Program. 2015. PMID: 26637733 Review.
-
[Classification, staging and prognostic indices for multiple myeloma].Nihon Rinsho. 2007 Dec;65(12):2161-6. Nihon Rinsho. 2007. PMID: 18069256 Review. Japanese.
Cited by
-
The MAPK/ERK signaling pathway involved in Raddeanin A induces apoptosis via the mitochondrial pathway and G2 phase arrest in multiple myeloma.Sci Rep. 2024 Nov 23;14(1):29061. doi: 10.1038/s41598-024-76465-z. Sci Rep. 2024. PMID: 39580496 Free PMC article.
-
Effect of monoclonal gammopathy in the progression of acute kidney injury and chronic kidney disease: a retrospective observational study.Clin Exp Nephrol. 2024 Nov 23. doi: 10.1007/s10157-024-02571-x. Online ahead of print. Clin Exp Nephrol. 2024. PMID: 39579299
-
The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA-CAR-T cell therapy: A retrospective study based on LEGEND-2.Hemasphere. 2024 Nov 19;8(11):e70054. doi: 10.1002/hem3.70054. eCollection 2024 Nov. Hemasphere. 2024. PMID: 39564538 Free PMC article.
-
Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease.Sci Rep. 2024 Nov 19;14(1):28557. doi: 10.1038/s41598-024-79537-2. Sci Rep. 2024. PMID: 39558020 Free PMC article.
-
Clinical characteristics of monoclonal immunoglobulin-associated renal disease: a retrospective cohort study.Clin Exp Nephrol. 2024 Nov 15. doi: 10.1007/s10157-024-02552-0. Online ahead of print. Clin Exp Nephrol. 2024. PMID: 39546082
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

